Drug Profile
Cancer therapeutics and diagnostics - MabCure
Alternative Names: anti-PROSCA; anti-PROSCA monoclonal antibodiesLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator MabCure
- Class Antibody diagnostics; Diagnostic agents; Monoclonal antibodies; Monoclonal antibody diagnostics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Colorectal cancer; Malignant melanoma; Ovarian cancer; Prostate cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Ovarian-cancer(Diagnosis) in Belgium (Parenteral)
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Ovarian-cancer(Diagnosis) in Thailand (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Belgium (Parenteral)